Literature DB >> 27643717

ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II.

Sughosh Dhakal1, Ranjana Advani, Leslie K Ballas, Bouthaina S Dabaja, Christopher R Flowers, Chul S Ha, Bradford S Hoppe, Nancy P Mendenhall, Monika L Metzger, John P Plastaras, Kenneth B Roberts, Ronald Shapiro, Sonali M Smith, Stephanie A Terezakis, Karen M Winkfield, Anas Younes, Louis S Constine.   

Abstract

This topic addresses the treatment of newly diagnosed patients with favorable prognosis stage I and II Hodgkin lymphoma. In most cases, combined modality therapy (chemotherapy followed by involved site radiation therapy) constitutes the current standard of care. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer-reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment. By combining the most recent medical literature and expert opinion, this revised guideline can aid clinicians in the appropriate use of combined modality therapy for favorable prognosis stage I and II Hodgkin lymphoma. Increasing information about the late effects of treatment has led to attempts to decrease toxicity by using less chemotherapy (decreased duration and/or intensity or different agents) and less radiation therapy (reduced volume and/or dose) while maintaining excellent efficacy.

Entities:  

Mesh:

Year:  2016        PMID: 27643717      PMCID: PMC7433865          DOI: 10.1097/COC.0000000000000331

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  64 in total

1.  Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment.

Authors:  A J Swerdlow; J A Barber; G V Hudson; D Cunningham; R K Gupta; B W Hancock; A Horwich; T A Lister; D C Linch
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

2.  Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group.

Authors:  Dennis A Eichenauer; Michael Fuchs; Annette Pluetschow; Beate Klimm; Teresa Halbsguth; Boris Böll; Bastian von Tresckow; Lucia Nogová; Peter Borchmann; Andreas Engert
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

3.  Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease.

Authors:  P M Mauch; L A Kalish; K C Marcus; L N Shulman; E Krill; N J Tarbell; B Silver; H Weinstein; S Come; G P Canellos; C N Coleman
Journal:  Cancer J Sci Am       Date:  1995 May-Jun

4.  Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

Authors:  John M M Raemaekers; Marc P E André; Massimo Federico; Theodore Girinsky; Reman Oumedaly; Ercole Brusamolino; Pauline Brice; Christophe Fermé; Richard van der Maazen; Manuel Gotti; Reda Bouabdallah; Catherine J Sebban; Yolande Lievens; Allessandro Re; Aspasia Stamatoullas; Frank Morschhauser; Pieternella J Lugtenburg; Elisabetta Abruzzese; Pierre Olivier; Rene-Olivier Casasnovas; Gustaaf van Imhoff; Tiana Raveloarivahy; Monica Bellei; Thierry van der Borght; Stephane Bardet; Annibale Versari; Martin Hutchings; Michel Meignan; Catherine Fortpied
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

5.  Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients.

Authors:  P L Zinzani; M Tani; S Fanti; L Alinari; G Musuraca; E Marchi; V Stefoni; P Castellucci; M Fina; M Farshad; S Pileri; M Baccarani
Journal:  Ann Oncol       Date:  2006-06-09       Impact factor: 32.976

6.  Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.

Authors:  V Diehl; M Sextro; J Franklin; M L Hansmann; N Harris; E Jaffe; S Poppema; M Harris; K Franssila; J van Krieken; T Marafioti; I Anagnostopoulos; H Stein
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

7.  Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up.

Authors:  Ronald C Chen; Michael S Chin; Andrea K Ng; Yang Feng; Donna Neuberg; Barbara Silver; Geraldine S Pinkus; Mary Ann Stevenson; Peter M Mauch
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

8.  Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study.

Authors:  Anthony J Swerdlow; Craig D Higgins; Paul Smith; David Cunningham; Barry W Hancock; Alan Horwich; Peter J Hoskin; Andrew Lister; John A Radford; Ama Z S Rohatiner; David C Linch
Journal:  J Natl Cancer Inst       Date:  2007-02-07       Impact factor: 13.506

9.  Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.

Authors:  P Carde; A Hagenbeek; M Hayat; M Monconduit; J Thomas; M J Burgers; E M Noordijk; A Tanguy; J H Meerwaldt; R Le Fur
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544

10.  Involved node radiation therapy: an effective alternative in early-stage hodgkin lymphoma.

Authors:  Maja V Maraldo; Marianne C Aznar; Ivan R Vogelius; Peter M Petersen; Lena Specht
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-11-29       Impact factor: 7.038

View more
  2 in total

Review 1.  Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma.

Authors:  Pamela B Allen; Jane N Winter
Journal:  Curr Oncol Rep       Date:  2019-03-27       Impact factor: 5.075

Review 2.  Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.

Authors:  Pamela B Allen; Leo I Gordon
Journal:  Clin Med Insights Oncol       Date:  2017-09-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.